VENMAX DRUGS AND PHARMACEUTICA Share Price

₹ 13.99

+₹0.35 (2.57%)
1D
Last updated 03 Nov, 2026, 09:57 IST
BSE: 531015
|
Pharmaceuticals

VENMAX DRUGS AND PHARMACEUTICA Share Price Today

As of 3 Nov 2026, VENMAX DRUGS AND PHARMACEUTICA share price is ₹13.99. The stock opened at ₹13.99, compared to its previous close of ₹13.64. During today's trading session, VENMAX DRUGS AND PHARMACEUTICA share price moved in the range of ₹13.64 to ₹13.99, with an average price of ₹13.82 for the day. Looking at its last 52-week, the stock has touched a low of ₹12.51 and a high of ₹31.49.

Share price over the last 1 day rose from 13.99 to 13.99, ranging between 13.64 and 13.99.
₹13.64
2.57% up today
₹13.99
1D LOW
1D HIGH

VENMAX DRUGS AND PHARMACEUTICA Stock Insights

Stock Performance
UnderperformingUnderperforming Nifty by 42.82 % in last 1 yr
VENMAX DRUGS AND PHARMACEUTICA stock performance
Open₹13.99
High₹13.99
Low₹13.64
Prev. close₹13.64
VENMAX DRUGS AND PHARMACEUTICA trading activity
Volume1,008
Average traded price₹13.64
Last traded time09:57:47 03 Nov
Last traded quantity5
Circuit
L
H
₹10.92
₹16.36
52-week
L
H
₹12.51
₹31.49
Mkt Cap Cr
19.39
P/E
70.47
P/B
0.93
ROA
1.66%
ROE
1.87%
ROCE
2.03%
Quick Ratio
7.46
EV/EBITDA
58.68

Based on fundamentals, this stock's

Performance: 1 out of 5, Very Poor
Performance
Very Poor
Venmax Drugs has not beaten FD return of 7%
Valuation: 1 out of 5, Overvalued
Valuation
Overvalued
Venmax Drugs appears overvalued compared to its peers
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROAROEROCEQuick RatioEV/EBITDA
Sun Pharmaceutical Industries4,24,202.4238.834.789.61%13.79%18.65%2.3122.27
Divis Laboratories2,57,902.7388.1715.3914.6%15.32%19.56%3.558.97
Torrent Pharmaceuticals1,74,402.4783.099.494.7%11.42%11.37%0.7533.6
Laurus Labs1,26,811.2895.1720.9211.58%22.11%20.91%0.6854.77
Zydus Lifesciences1,24,089.4827.024.588.57%18.59%17.35%0.9116.42
Dr. Reddy's Laboratories1,12,698.5340.842.94.79%7.21%8.58%1.3519.05
Cipla1,11,486.1439.063.156.6%8.18%10.8%2.521.03
Mankind Pharma1,02,195.6245.155.817.82%12.76%14.68%0.7425.01
Aurobindo Pharma96,536.9026.022.556.34%9.25%11.76%1.1512.38
Lupin91,870.1616.454.0714.47%23.76%24.88%1.429.83

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

VENMAX DRUGS AND PHARMACEUTICA Company Background

ISIN
INE154G01022
Sector Market Cap
₹ 19.39 Cr

Venmax Drugs and Pharmaceuticals Limited is an India-based company. The Company is engaged in the business of pharmaceutical products, drug intermediaries and active pharmaceutical ingredients (API’s). It is developing oncology products through research and development (R&D).

VENMAX DRUGS AND PHARMACEUTICA Financial Highlights

  • Revenue: VENMAX DRUGS AND PHARMACEUTICA reported revenue of ₹8.18 crore in FY26 vs ₹1.86 crore in FY25. It showed an increase of 339.78% on a yearly basis.
  • Operating Profit: VENMAX DRUGS AND PHARMACEUTICA reported an operating profit of ₹0.28 crore in FY26 vs ₹0.01 crore in FY25. It showed an increase of 2,900.00% on a year-on-year basis.
  • Net Profit: VENMAX DRUGS AND PHARMACEUTICA reported a net profit of ₹0.25 crore in FY26 vs ₹0.01 crore in FY25. It showed an increase of 2,600.00% on a yearly basis.

VENMAX DRUGS AND PHARMACEUTICA Quarterly Result Highlights

  • VENMAX DRUGS AND PHARMACEUTICA reported revenue of ₹2.48 crore in Jun 2026, compared with ₹4.03 crore in Mar 2026, representing a decrease of 38.46% on a quarter-on-quarter (QoQ) basis.
  • VENMAX DRUGS AND PHARMACEUTICA reported an operating profit of ₹0.12 crore in Jun 2026, compared with ₹0.10 crore in Mar 2026, representing an increase of 20.00% on a quarter-on-quarter (QoQ) basis.
  • VENMAX DRUGS AND PHARMACEUTICA reported a profit of ₹0.12 crore in Jun 2026, compared with ₹0.11 crore in Mar 2026, reflecting an increase of 9.09% on a QoQ basis.
  • The earnings per share (EPS) of VENMAX DRUGS AND PHARMACEUTICA stood at ₹0.21 during Jun 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Promoters
10.46%
FII
0.00%
Other DII
0.00%
Retail and other
89.54%
Mutual funds
0.00%
Foreign Institutional Investor (FII)
FII shareholding by period
Dec 20250.00%
Mar 20260.00%
Jun 20260.00%
Sep 20260.00%

VENMAX DRUGS AND PHARMACEUTICA Investment Returns

1 day
+1.87%
1 week
-1.66%
1 month
-5.93%
1 year
-51.29%
3 years
+107.29%
5 years
+107.29%

VENMAX DRUGS AND PHARMACEUTICA Share Price History

VENMAX DRUGS AND PHARMACEUTICA share price history by day, showing open and close prices and the percentage change
Day
Open / Close
Change %
02 Nov 26
₹13.39 / ₹13.64
+1.87%
30 Oct 26
₹12.51 / ₹13.39
+3.24%
29 Oct 26
₹13.06 / ₹12.97
-0.69%
28 Oct 26
₹15.00 / ₹13.06
-6.71%
Show more

VENMAX DRUGS AND PHARMACEUTICA Financials

Full statement

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹8.02₹0.81₹0.00₹0.00
Other Income₹0.16₹1.05₹0.20₹0.42
Total Revenue₹8.19₹1.86₹0.20₹0.42
Total Expenses₹7.91₹1.87₹0.11₹0.19
Profit Before Tax₹0.28-₹0.01₹0.09₹0.23
Tax₹0.03₹0.00₹0.02₹0.00
Profit After Tax₹0.25-₹0.01₹0.06₹0.23
EPS - Basic₹0.21-₹0.02₹0.12₹0.43
EPS - Diluted₹0.21-₹0.02₹0.12₹0.43

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹0.28-₹0.01₹0.09₹0.23
Income before WC changes₹0.28₹0.01₹0.09₹0.23
Change in Assets-₹12.29-₹2.63₹0.13-₹0.09
Change in Liabilities₹1.05₹0.33-₹0.19-₹0.14
Change in WC-₹11.25-₹2.30-₹0.07-₹0.24
Cash flow from Operations-₹11.00-₹2.29₹0.00₹0.00
Cash flow from Investing₹0.00₹0.00₹0.00₹0.00
Cash flow from Financing₹9.74₹4.77₹0.00₹0.00
Total Cash Flow-₹1.26₹2.48₹0.00₹0.00
Cash (Start of the year)₹2.48₹0.00₹0.00₹0.00
Cash (End of the year)₹1.22₹2.48₹0.00₹0.00

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹0.04₹0.04₹0.07₹0.07
Current Assets₹16.16₹5.13₹0.02₹0.14
Total Assets₹16.20₹5.17₹0.08₹0.21
Current Liabilities₹2.03₹0.71₹0.73₹0.92
Net Current Asset₹14.13₹4.42-₹0.71-₹0.78
Non-Current Liabilities₹0.05₹0.05₹0.00₹0.00
Equity Capital₹14.12₹4.41-₹0.65-₹0.71
Total Equity & Liabilities₹16.20₹5.17₹0.08₹0.21
* All values are in INR Crore
VENMAX DRUGS AND PHARMACEUTICA market depth
Bid quantityBid priceAsk priceAsk quantity
400013.6413.9928
160012.82141
20112.614.7815
11214.81655
111.9914.9500
Total bid quantity5,803
Total ask quantity2,199
VENMAX DRUGS AND PHARMACEUTICA technical summary
Bearish indicators1
Neutral indicators6
Bullish indicators1
OverallNeutral
by SEBI experts

Expert Pick

EXPPICK
Stop-loss
Stop-loss is locked. Sign in to view.
Entry price
Entry price is locked. Sign in to view.
Target
Target is locked. Sign in to view.
Indicator
Value
Verdict
RSI (14)
43.66
Neutral
ATR (14)
1.44
Neutral
STOCH(9,6)
30.21
Neutral
STOCH RSI (14)
46.87
Neutral
ADX(9)
18.49
Bullish
UO(9)
38.91
Neutral
ROC(12)
-7.15
Bearish
WillR(14)
-70.11
Neutral
Period
Simple value
Exponential vaue
5D
13.41
13.54
10D
13.91
13.79
20D
14.23
14.13
50D
14.69
14.98
100D
16.4
16.66
Volume trend — traded volume by day
3 Nov0L
2 Nov0L
30 Oct0L
29 Oct0L
28 Oct0L
27 Oct0L
Average0L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks

VENMAX DRUGS AND PHARMACEUTICA
Pharmaceuticals
Add Stock
Add Another

VENMAX DRUGS AND PHARMACEUTICA Returns Calculator

Top Gainers

TRIDENT Share Price
₹24.59
+2.38 (+10.72%)
KRBL Share Price
₹398.05
+35.05 (+9.66%)
GRSE Share Price
₹2212.00
+165.2 (+8.07%)
MARICO Share Price
₹854.80
+56.25 (+7.04%)
MOTILALOFS Share Price
₹1023.90
+59.5 (+6.17%)
See more

Top Losers

KEC Share Price
₹323.55
-25.45 (-7.29%)
GNFC Share Price
₹480.85
-30.15 (-5.9%)
PRAJIND Share Price
₹260.50
-10.63 (-3.92%)
GESHIP Share Price
₹1549.10
-51.3 (-3.21%)
BIOCON Share Price
₹345.05
-9.65 (-2.72%)
See more

VENMAX DRUGS AND PHARMACEUTICA Share Price FAQs

Please be aware that VENMAX DRUGS AND PHARMACEUTICA stock prices are subject to continuous fluctuations due to various factors.